FDA Officials Recommend Long-Term Follow-Up for CAR-T Therapies in Autoimmune Diseases
February 2, 2026 — Global Biotech NewsSilver Spring, MD, USA — Senior officials at the U.S. Food and Drug Administration (FDA) have urged biotechnology companies to implement long-term monitoring of...
More+
FDA Clears IND for AAV-Based Gene Therapy Targeting High-Grade Glioma
February 2026 — Global Biotech NewsSan Francisco, CA / USA — The U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for SRN-101, an AAV-based immuno-ge...
More+
Global Cell & Gene Therapy Industry Shows Strong Growth Across Approvals, Revenue and Deals
February 2026 — Industry NewsThe global cell and gene therapy (CGT) sector continues to expand, with recent industry data highlighting a combination of strong product revenues, increasing regulatory ...
More+
CARsgen Administers First Dose of Allogeneic CAR-T Therapy to Patient With Systemic Lupus Erythematosus
February 2026 — Global Biotech NewsShanghai, China / Global — CARsgen Therapeutics Holdings Ltd., a clinical-stage biotechnology company focused on innovative chimeric antigen receptor T-cell (CAR-T...
More+
_20251128152047.webp "Historic Breakthrough! The World's First iPSC Cell Therapy Products Approved in Japan")
Historic Breakthrough! The World's First iPSC Cell Therapy Products Approved in Japan
On February 19, 2026, Japan's Ministry of Health, Labour and Welfare (MHLW) granted conditional and time-limited approval to the world's first two induced pluripotent stem cell (iPSC)–based r...
More+
_20260130144401.webp "Lentiviral Vectors Power Next Wave of In Vivo CAR-T Development")
Lentiviral Vectors Power Next Wave of In Vivo CAR-T Development
March 2026 — Global Biotech NewsLentiviral vector technology continues to play a central role in the evolution of CAR-T cell therapies, as researchers advance strategies aimed at delivering chimeric ...
More+
86 198 5711 6962 
info@hillgene.com 
English